Moleculin Biotech Inc (MBRX.OQ)
MBRX.OQ on NASDAQ Stock Exchange Capital Market
1.85USD
20 Apr 2018
1.85USD
20 Apr 2018
Change (% chg)
$-0.02 (-1.07%)
$-0.02 (-1.07%)
Prev Close
$1.87
$1.87
Open
$1.85
$1.85
Day's High
$1.85
$1.85
Day's Low
$1.84
$1.84
Volume
2,867
2,867
Avg. Vol
136,930
136,930
52-wk High
$3.74
$3.74
52-wk Low
$0.71
$0.71
Revenue & Earnings Per Share
Revenue* | Earnings Per Share** | ||
---|---|---|---|
FY 2017 | Dec '17 | 0.00 | -0.150 |
Sep '17 | 0.00 | -0.140 | |
Jun '17 | 0.00 | -0.192 | |
Mar '17 | 0.00 | -0.023 | |
FY 2016 | Dec '16 | 0.00 | -0.311 |
Sep '16 | 0.00 | -0.124 | |
Jun '16 | 0.00 | -0.088 | |
Mar '16 | 0.00 | -0.023 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
# of Estimates | Mean | High | Low | 1 Year Ago | |
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
Quarter Ending Sep-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
Year Ending Dec-18 | 1 | 0.00 | 0.00 | 0.00 | 0.00 |
Year Ending Dec-19 | 1 | 0.00 | 0.00 | 0.00 | -- |
Earnings (per share) | |||||
Quarter Ending Jun-18 | 1 | -0.14 | -0.14 | -0.14 | -- |
Quarter Ending Sep-18 | 1 | -0.14 | -0.14 | -0.14 | -- |
Year Ending Dec-18 | 1 | -0.57 | -0.57 | -0.57 | -0.36 |
Year Ending Dec-19 | 1 | -0.62 | -0.62 | -0.62 | -- |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
Company | industry | sector | ||
---|---|---|---|---|
P/E Ratio (TTM) | -- | 30.95 | 32.74 | |
P/E High - Last 5 Yrs. | -- | 40.70 | 45.72 | |
P/E Low - Last 5 Yrs. | -- | 23.63 | 24.22 | |
Beta | -- | 0.89 | 0.88 | |
Price to Sales (TTM) | -- | 3.94 | 5.71 | |
Price to Book (MRQ) | 2.57 | 4.80 | 5.37 | |
Price to Tangible Book (MRQ) | 6.14 | 5.61 | 6.95 | |
Price to Cash Flow (TTM) | -- | 22.91 | 23.32 | |
% Owned Institutions | 5.13 | 1.21 | 2.17 |
Dividends
Company | industry | sector | ||
---|---|---|---|---|
Dividend Yield | -- | 1.56 | 1.50 | |
Dividend Yield - 5 Year Avg | -- | 1.57 | 1.51 | |
Dividend 5 Year Growth Rate | -- | 4.47 | 5.32 | |
Payout Ratio(TTM) | -- | 45.35 | 43.29 |
Growth Rates
Company | industry | sector | ||
---|---|---|---|---|
Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 3.69 | 9.21 | |
Sales (TTM) vs TTM 1 Yr. Ago | -- | 4.83 | 5.69 | |
Sales - 5 Yr. Growth Rate | -- | 10.08 | 10.32 | |
EPS (MRQ) vs Qtr. 1 Yr. Ago | -138.19 | 16.36 | 19.36 | |
EPS (TTM) vs TTM 1 Yr. Ago | -- | -- | -- | |
EPS - 5 Yr. Growth Rate | -- | 9.87 | 10.76 | |
Capital Spending - 5 Yr. Growth Rate | -- | 15.52 | 15.47 |
Financial Strength
Company | industry | sector | |
---|---|---|---|
Quick Ratio (MRQ) | -- | 2.12 | 2.19 |
Current Ratio (MRQ) | 5.51 | 2.90 | 2.98 |
LT Debt to Equity (MRQ) | 0.00 | 9.88 | 12.18 |
Total Debt to Equity (MRQ) | 0.00 | 13.86 | 16.45 |
Interest Coverage (TTM) | -- | 35.89 | 32.81 |
Profitability Ratios
Company | industry | sector | ||
---|---|---|---|---|
Gross Margin (TTM) | -- | 54.81 | 54.44 | |
Gross Margin - 5 Yr. Avg. | -- | 52.15 | 52.20 | |
EBITD Margin (TTM) | -- | -- | -- | |
EBITD - 5 Yr. Avg | -- | 18.57 | 10.96 | |
Operating Margin (TTM) | -- | 14.36 | 4.73 | |
Operating Margin - 5 Yr. Avg. | -- | 14.52 | 6.40 | |
Pre-Tax Margin (TTM) | -- | 14.82 | 5.57 | |
Pre-Tax Margin - 5 Yr. Avg. | -- | 14.90 | 6.81 | |
Net Profit Margin (TTM) | -- | 11.08 | 1.87 | |
Net Profit Margin - 5 Yr. Avg. | -- | 11.20 | 3.09 | |
Effective Tax Rate (TTM) | -- | 23.16 | 23.04 | |
Effective Tax Rate - 5 Yr. Avg. | -- | 23.42 | 23.96 |
Efficiency
Company | industry | sector | ||
---|---|---|---|---|
Revenue/Employee (TTM) | 0 | 938,079,949 | 846,830,978 | |
Net Income/Employee (TTM) | -3,304,195 | 110,368,367 | 99,616,195 | |
Receivable Turnover (TTM) | -- | 5.63 | 5.78 | |
Inventory Turnover (TTM) | -- | 2.59 | 3.35 | |
Asset Turnover (TTM) | 0.00 | 0.95 | 0.92 |
Management Effectiveness
Company | industry | sector | ||
---|---|---|---|---|
Return on Assets (TTM) | -32.65 | 11.40 | 10.95 | |
Return on Assets - 5 Yr. Avg. | -- | 12.91 | 12.31 | |
Return on Investment (TTM) | -35.48 | 14.84 | 14.38 | |
Return on Investment - 5 Yr. Avg. | -- | 16.88 | 16.10 | |
Return on Equity (TTM) | -36.21 | 16.34 | 16.07 | |
Return on Equity - 5 Yr. Avg. | -- | 17.98 | 17.39 |
1 Year | 3 Year | 5 Year | |
---|---|---|---|
Sales % | -- | -- | -- |
EPS (TTM) % | -1,458.84 | -- | -- |
Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Moleculin Biotech Inc
Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
---|---|---|---|---|
4 Week | -6.82 | -10.03 | 36 | 23 |
13 Week | 69.66 | 61.39 | 99 | 34 |
26 Week | 192.86 | 170.60 | 99 | 29 |
52 Week | -51.86 | -59.20 | 15 | 12 |
YTD | 7.89 | -5.25 | 99 | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Moleculin Biotech Inc - Has Been Able To Show Promising Tumor Suppression Activity With Its Inhibitor Of Glycolysis, Wp1122
- BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor
- BRIEF-Moleculin Announces Polish Approval For Leukemia Clinical Trial
- BRIEF-Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA
- BRIEF-Moleculin Biotech Q3 loss per share $0.14
Institutional Holders
% Shares Owned: | 8.80% |
# of Holders: | 16 |
Total Shares Held: | 2,266,545 |
3 Mo. Net Change: | 1,502,350 |
# New Positions: | 1 |
# Closed Positions: | 0 |
# Increased Positions: | 1 |
# Reduced Positions: | 0 |
# Net Buyers: | 1 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.